Taminadenant
Product Specifications
UNSPSC Description
Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response[1][2].
Target Antigen
Adenosine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Taminadenant.html
Purity
99.84
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
BrC(C(N1C=CC=N1)=NC(N2C=CC=N2)=N3)=C3N
Molecular Weight
306.12
References & Citations
[1]Núñez F, et al. PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders. Front Pharmacol. 2018 Oct 19;9:1200.|[2]Chiappori AA, et al. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Jun 1;28(11):2313-2320.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-109139/Taminadenant-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-109139/Taminadenant-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1337962-47-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
